Shares of Flexion Therapeutics Inc (NASDAQ:FLXN) have earned an average rating of “Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $106.25.

A number of equities analysts recently commented on FLXN shares. Janney Montgomery Scott lifted their price objective on Flexion Therapeutics to $570.00 and gave the stock a “fair value” rating in a research note on Tuesday, October 10th. Wells Fargo & Co set a $39.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Friday, October 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Flexion Therapeutics in a research note on Sunday, September 17th. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Finally, Royal Bank of Canada set a $44.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a research note on Sunday, October 29th.

In other Flexion Therapeutics news, insider Neil Bodick purchased 2,700 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were purchased at an average cost of $24.49 per share, with a total value of $66,123.00. Following the completion of the purchase, the insider now owns 64,605 shares in the company, valued at $1,582,176.45. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Michael D. Clayman purchased 5,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was acquired at an average cost of $23.60 per share, for a total transaction of $118,000.00. Following the completion of the purchase, the insider now owns 35,395 shares of the company’s stock, valued at approximately $835,322. The disclosure for this purchase can be found here. 15.98% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. raised its position in shares of Flexion Therapeutics by 0.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock worth $2,047,000 after purchasing an additional 513 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Flexion Therapeutics during the second quarter worth approximately $425,000. JPMorgan Chase & Co. raised its position in shares of Flexion Therapeutics by 46.0% during the second quarter. JPMorgan Chase & Co. now owns 167,350 shares of the specialty pharmaceutical company’s stock worth $3,384,000 after purchasing an additional 52,763 shares during the period. Fiduciary Trust Co. acquired a new position in shares of Flexion Therapeutics during the second quarter worth approximately $101,000. Finally, Schroder Investment Management Group raised its position in shares of Flexion Therapeutics by 29.3% during the second quarter. Schroder Investment Management Group now owns 509,427 shares of the specialty pharmaceutical company’s stock worth $10,474,000 after purchasing an additional 115,413 shares during the period. 72.78% of the stock is currently owned by hedge funds and other institutional investors.

Flexion Therapeutics (NASDAQ:FLXN) traded up $0.47 during trading on Friday, hitting $26.45. The company had a trading volume of 653,879 shares, compared to its average volume of 956,921. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. The firm has a market capitalization of $992.95, a price-to-earnings ratio of -7.51 and a beta of 1.14. Flexion Therapeutics has a one year low of $16.51 and a one year high of $32.25.

TRADEMARK VIOLATION WARNING: “Flexion Therapeutics Inc (FLXN) Given Average Rating of “Buy” by Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/12/flexion-therapeutics-inc-flxn-given-average-rating-of-buy-by-brokerages.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.